• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Trian Comments on Solventum's Sale of its Purification & Filtration Business

    2/26/25 2:50:51 PM ET
    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials
    Get the next $SOLV alert in real time by email

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE:TMO) ("Thermo Fisher"). Trian issued the following statement:

    "Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company's value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the division's differentiated technology and material science – attributes inherited from 3M which are present at Solventum's remaining businesses, and which we believe remain underappreciated by the market today.

    Notably, in conjunction with the acquisition, Thermo Fisher issued public comments which Trian believes confirm that there is a meaningful cost reduction opportunity at Solventum:

    "Excluding financing costs, the transaction is expected to be accretive by $0.28 in that period. This reflects the very strong day one cost synergies when Solventum's allocated segment costs are replaced by lower run rate costs within Thermo Fisher."

    Thermo Fisher's release goes on to suggest that it believes it can more than double the profitability of Purification & Filtration under its corporate umbrella, relative to the business' current profit as part of Solventum, with much of that improvement driven by lower allocated costs.

    Trian, in its January letter to shareholders, highlighted that Solventum has a significant opportunity to right size costs and realize higher margins while reinvesting more in growth.

    Inside of 3M, Solventum averaged 3-4% organic growth and a 26-27% EBIT margin. Trian believes that Solventum should be able to deliver faster organic growth and higher margins as a focused, standalone company. Trian looks forward to the Company delivering a Long Range Plan that reflects the business' potential when it hosts its investor day in March."

    About Trian Fund Management, L.P.

    Founded in 2005, Trian Fund Management, L.P. ("Trian") is a multi-billion dollar investment management firm. Trian is a highly engaged shareowner that combines concentrated public equity ownership with operational expertise. Leveraging the 50+ years' operating experience of our Founding Partners, Nelson Peltz and Peter May, Trian seeks to invest in high quality but undervalued and underperforming public companies and to work collaboratively with management teams and boards to help companies execute operational and strategic initiatives designed to drive long-term sustainable earnings growth for the benefit of all shareholders.

    Media Contacts:

    Anne A. Tarbell

    (212) 451-3030

    [email protected]

    Paul Caminiti / Pamela Greene / Jacqueline Zuhse

    Reevemark

    (212) 433-4600

    [email protected]

    Investor Contact:

    Matt Underhill

    (212) 451-3171

    [email protected]

    Disclaimer

    Except as otherwise set forth in this press release, the views expressed in this press release reflect the opinions of Trian Fund Management, L.P. and its affiliates ("Trian"), and are based on publicly available information with respect to Solventum Corporation (the "Company"). Trian recognizes that there may be confidential information in the possession of the Company that could lead it or others to disagree with Trian's conclusions. Trian reserves the right to change any of its opinions expressed herein at any time as it deems appropriate and disclaims any obligation to notify the market or any other party of any such change, except as required by law. Trian disclaims any obligation to update the information or opinions contained in this press release. For the avoidance of doubt, this press release is not affiliated with or endorsed by the Company.

    This press release is provided merely as information and is not intended to be, nor should it be construed as, an offer to sell or a solicitation of an offer to buy any security nor as a recommendation to purchase or sell any security. Funds managed by Trian currently beneficially own shares of the Company. These funds are in the business of trading – buying and selling– securities and intend to continue trading in the securities of the Company. You should assume such funds may from time to time sell all or a portion of their holdings of the Company in open market transactions or otherwise (including via short sales), buy additional shares (in open market or privately negotiated transactions or otherwise), or trade in options, puts, calls, swaps or other derivative instruments relating to such shares.

    Some of the materials in this press release contain forward-looking statements. All statements contained herein that are not clearly historical in nature or that necessarily depend on future events are forward-looking, and the words "anticipate," "believe," "expect," "potential," "could," "opportunity," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. The projected results and statements contained herein that are not historical facts are based on current expectations, speak only as of the date of these materials and involve risks, uncertainties and other factors that may cause actual results, performances or achievements to be materially different from any future results, performances or achievements expressed or implied by such projected results and statements. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Trian.

    Certain financial projections and statements made herein have been derived or obtained from filings made with the Securities and Exchange Commission ("SEC") or other regulatory authorities and from other third-party reports. Trian shall not be responsible or have any liability for any misinformation contained in any third-party, SEC or other regulatory filing or third-party report.

    There is no assurance or guarantee with respect to the prices at which any securities of the Company will trade, and such securities may not trade at prices that may be implied herein. The estimates, projections and potential impact of the opportunities identified by Trian herein are based on assumptions that Trian believes to be reasonable as of the date of this press release, but there can be no assurance or guarantee (i) that any of the proposed actions set forth in this press release will be completed, (ii) that the actual results or performance of the Company will not differ, and such differences may be material, or (iii) that any of the assumptions provided in this press release are accurate.  This press release does not recommend the purchase or sale of any security.



    Primary Logo

    Get the next $SOLV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SOLV
    $TMO

    CompanyDatePrice TargetRatingAnalyst
    Thermo Fisher Scientific Inc
    $TMO
    3/27/2026$610.00Buy
    DZ Bank
    Solventum Corporation
    $SOLV
    3/24/2026$60.00Sell
    Rothschild & Co Redburn
    Solventum Corporation
    $SOLV
    1/26/2026$97.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Solventum Corporation
    $SOLV
    1/20/2026$100.00Neutral → Outperform
    Mizuho
    Thermo Fisher Scientific Inc
    $TMO
    12/11/2025$660.00Neutral → Buy
    Citigroup
    Thermo Fisher Scientific Inc
    $TMO
    12/9/2025$685.00Buy
    Goldman
    Thermo Fisher Scientific Inc
    $TMO
    12/8/2025$750.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Thermo Fisher Scientific Inc
    $TMO
    12/2/2025$670.00Overweight
    Morgan Stanley
    More analyst ratings

    $SOLV
    $TMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Vice President Shafer Michael D sold $802,536 worth of shares (1,607 units at $499.40), decreasing direct ownership by 7% to 20,950 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/12/26 4:23:10 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Director Wendell Amy Mcbride bought $100,344 worth of shares (1,475 units at $68.03), increasing direct ownership by 41% to 5,039 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    3/11/26 6:31:11 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    New insider Meyer James claimed ownership of 5,891 shares (SEC Form 3)

    3 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    3/10/26 4:07:46 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $SOLV
    $TMO
    SEC Filings

    View All

    SEC Form DEFA14A filed by Solventum Corporation

    DEFA14A - Solventum Corp (0001964738) (Filer)

    3/27/26 4:17:58 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form DEF 14A filed by Solventum Corporation

    DEF 14A - Solventum Corp (0001964738) (Filer)

    3/27/26 4:15:44 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Solventum Corporation

    SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

    3/27/26 1:18:06 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    $TMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.

    Further strengthens Thermo Fisher's position as the trusted partner to pharma and biotech customers, delivering important customer benefits Attractive return profile given high growth and strong margin profile of Clario, and meaningful synergies – reflecting the company's disciplined approach to capital deployment Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced the completion of its acquisition of Clario Holdings, Inc., a leading provider of endpoint data solutions for clinical trials, for $8.875 billion in cash, plus potential additional earnout and other payments, largely dependent on performance. With the transaction complete, the Clario

    3/24/26 8:00:00 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Solventum to Participate in the 2026 KeyBanc Healthcare Forum

    ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18, 2026, beginning at approximately 10:30 a.m. EDT. More information about this event, including access to the live webcast and the webcast replay, will be available at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal

    3/11/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    $SOLV
    $TMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Wendell Amy Mcbride bought $100,344 worth of shares (1,475 units at $68.03), increasing direct ownership by 41% to 5,039 units (SEC Form 4)

    4 - Solventum Corp (0001964738) (Issuer)

    3/11/26 6:31:11 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Director Chai Nelson sold $8,449 worth of shares (16 units at $528.09) and bought $11,038 worth of shares (20 units at $551.90), increasing direct ownership by 0.03% to 14,252 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    2/21/25 4:19:32 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Boxer Michael A bought $2,105 worth of shares (4 units at $526.15), increasing direct ownership by 0.03% to 13,101 units (SEC Form 4)

    4 - THERMO FISHER SCIENTIFIC INC. (0000097745) (Issuer)

    10/6/23 4:23:51 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    $SOLV
    $TMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    DZ Bank initiated coverage on Thermo Fisher with a new price target

    DZ Bank initiated coverage of Thermo Fisher with a rating of Buy and set a new price target of $610.00

    3/27/26 8:52:59 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Rothschild & Co Redburn initiated coverage on Solventum with a new price target

    Rothschild & Co Redburn initiated coverage of Solventum with a rating of Sell and set a new price target of $60.00

    3/24/26 8:51:05 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Solventum upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Solventum from Sector Weight to Overweight and set a new price target of $97.00

    1/26/26 8:32:07 AM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    $TMO
    Financials

    Live finance-specific insights

    View All

    Solventum Reports Fourth Quarter 2025 Financial Results and Introduces 2026 Full-Year Guidance

    Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

    2/26/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in thei

    2/25/26 4:15:00 PM ET
    $TMO
    Industrial Machinery/Components
    Industrials

    Solventum to Report Fourth Quarter and Full Year Fiscal 2025 Earnings on February 26, 2026

    ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

    2/3/26 4:05:00 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    $SOLV
    $TMO
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Henry Schein Names Frederick M. Lowery as Chief Executive Officer

    Industry veteran brings more than 20 years of healthcare distribution experience and operational excellence Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of healthcare solutions to office-based dental and medical professionals, today announced the appointment of Frederick M. Lowery as its new Chief Executive Officer ("CEO"), effective March 2, 2026, at which time he will join the Board of Directors. Mr. Lowery succeeds Stanley M. Bergman, who will step down as CEO after 35 years and continue to serve as Chairman of the Board to ensure a smooth and effective leadership transition. This press release features multimedia. View the full release here: https://www.businesswire

    1/12/26 7:00:00 AM ET
    $HSIC
    $TMO
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $SOLV
    $TMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/12/24 5:47:11 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Solventum Corporation

    SC 13G/A - Solventum Corp (0001964738) (Subject)

    11/4/24 1:47:43 PM ET
    $SOLV
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Thermo Fisher Scientific Inc (Amendment)

    SC 13G/A - THERMO FISHER SCIENTIFIC INC. (0000097745) (Subject)

    2/9/23 11:35:13 AM ET
    $TMO
    Industrial Machinery/Components
    Industrials